-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] In recent years, with the advancement of new pharmaceutical policies such as centralized procurement and medical insurance, the pharmaceutical market environment has undergone tremendous chang.
In order to adapt to the market environment, pharmaceutical companies have frequently adjusted their business, and the accompanying changes in senior management the no.
Recently, a large number of senior executives of pharmaceutical companies have reported resignati.
Among them, within one day of May 14 alone, many pharmaceutical companies issued announcements about the resignation of executives, including Kangmei Pharmaceutical, Celis Medical, and People's Pharma.
Kangmei Pharmaceutical's director resigns Kangmei Pharmaceutical announced that it has recently received a resignation report from the company's director Yang Weiro.
Due to work adjustment, Yang Weirong resigned as a director and member of the strategy committee of the compa.
After his resignation, .
Yang Weirong no longer holds any positions in the compa.
In addition, the company held the third extraordinary meeting of the ninth board of directors in 2022 on May 13, 2022, and reviewed and approved the "Proposal on the Appointment of .
Liu Xinquan as the Deputy General Manager of the Company", "On the Appointment of .
Li Zebin as the Company The Proposal of Assistant General Manager", after review by the Nomination Committee of the Board of Directors, it was agreed to appoint Liu Xinquan as the company's deputy general manager and Li Zebin as the company's assistant to the general manag.
According to the data, Kangmei Pharmaceutical is a listed company that focuses on the production and sales of Chinese herbal decoction pieces, takes "wisdom +" big health as a service platform, and implements the integrated operation of the whole industry chain of Chinese medici.
The company's 2022 first quarter results announcement stated that the revenue was about 934 million yuan; the net profit loss attributable to shareholders of the listed company was about 111 million yuan; the basic earnings per share lost 008 yu.
The deputy general manager of Celis Medical resign.
Celis Medical issued an announcement saying that the board of directors recently received a written resignation report submitted by the company's deputy general manager Huang Yong.
Huang Yongxi resigned as the company's deputy general manager for personal reaso.
After Huang Yongxi resigned, he no longer held any positions in the compa.
According to the data, Celis Medical focuses on the intensive marketing and service business of medical inspection, the agency of in vitro diagnostic products, and the research and development, production and sales of autonomous in vitro diagnostic produc.
In the first quarter of 2022, the company achieved revenue of 578 million yuan, a year-on-year increase of 101%; net profit attributable to shareholders of the listed company was 21854 million yuan, a year-on-year increase of 310
On the same day, the People's Pharmacy announced that the board of directors had recently received a written resignation report from Zhu Jingyang, the company's vice president and chief financial offic.
Zhu Jingyang applied to resign from the position of vice president and chief financial officer of the company due to personal reasons, and will no longer hold any position in the company after resignati.
According to the relevant provisions of the "Articles of Association", after the nomination of the company's president Wang Li and the review by the nomination, remuneration and appraisal committee of the board of directors, it was agreed to appoint Wen Jiefeng as the company's chief financial officer and chief financial offic.
The term of the fourth board of directors expir.
According to the data, People's Pharmacy is a large-scale pharmaceutical chain enterprise developed from a single private pharma.
It is one of the leading domestic chain pharmaci.
The 2021 annual report shows that People's Pharmacy has expanded to 2,223 franchised stores in more than ten provinces and citi.
In the first quarter of 2022, People's Pharmacy actively overcame the impact of the epidemic, and the year-on-year growth rate of operating income increased month by mon.
During the reporting period, the company achieved operating income of 141 billion yuan, a year-on-year increase of 181%; net profit attributable to shareholders of the listed company was 242 million yuan, a year-on-year increase of 2
In order to adapt to the market environment, pharmaceutical companies have frequently adjusted their business, and the accompanying changes in senior management the no.
Recently, a large number of senior executives of pharmaceutical companies have reported resignati.
Among them, within one day of May 14 alone, many pharmaceutical companies issued announcements about the resignation of executives, including Kangmei Pharmaceutical, Celis Medical, and People's Pharma.
Kangmei Pharmaceutical's director resigns Kangmei Pharmaceutical announced that it has recently received a resignation report from the company's director Yang Weiro.
Due to work adjustment, Yang Weirong resigned as a director and member of the strategy committee of the compa.
After his resignation, .
Yang Weirong no longer holds any positions in the compa.
In addition, the company held the third extraordinary meeting of the ninth board of directors in 2022 on May 13, 2022, and reviewed and approved the "Proposal on the Appointment of .
Liu Xinquan as the Deputy General Manager of the Company", "On the Appointment of .
Li Zebin as the Company The Proposal of Assistant General Manager", after review by the Nomination Committee of the Board of Directors, it was agreed to appoint Liu Xinquan as the company's deputy general manager and Li Zebin as the company's assistant to the general manag.
According to the data, Kangmei Pharmaceutical is a listed company that focuses on the production and sales of Chinese herbal decoction pieces, takes "wisdom +" big health as a service platform, and implements the integrated operation of the whole industry chain of Chinese medici.
The company's 2022 first quarter results announcement stated that the revenue was about 934 million yuan; the net profit loss attributable to shareholders of the listed company was about 111 million yuan; the basic earnings per share lost 008 yu.
The deputy general manager of Celis Medical resign.
Celis Medical issued an announcement saying that the board of directors recently received a written resignation report submitted by the company's deputy general manager Huang Yong.
Huang Yongxi resigned as the company's deputy general manager for personal reaso.
After Huang Yongxi resigned, he no longer held any positions in the compa.
According to the data, Celis Medical focuses on the intensive marketing and service business of medical inspection, the agency of in vitro diagnostic products, and the research and development, production and sales of autonomous in vitro diagnostic produc.
In the first quarter of 2022, the company achieved revenue of 578 million yuan, a year-on-year increase of 101%; net profit attributable to shareholders of the listed company was 21854 million yuan, a year-on-year increase of 310
On the same day, the People's Pharmacy announced that the board of directors had recently received a written resignation report from Zhu Jingyang, the company's vice president and chief financial offic.
Zhu Jingyang applied to resign from the position of vice president and chief financial officer of the company due to personal reasons, and will no longer hold any position in the company after resignati.
According to the relevant provisions of the "Articles of Association", after the nomination of the company's president Wang Li and the review by the nomination, remuneration and appraisal committee of the board of directors, it was agreed to appoint Wen Jiefeng as the company's chief financial officer and chief financial offic.
The term of the fourth board of directors expir.
According to the data, People's Pharmacy is a large-scale pharmaceutical chain enterprise developed from a single private pharma.
It is one of the leading domestic chain pharmaci.
The 2021 annual report shows that People's Pharmacy has expanded to 2,223 franchised stores in more than ten provinces and citi.
In the first quarter of 2022, People's Pharmacy actively overcame the impact of the epidemic, and the year-on-year growth rate of operating income increased month by mon.
During the reporting period, the company achieved operating income of 141 billion yuan, a year-on-year increase of 181%; net profit attributable to shareholders of the listed company was 242 million yuan, a year-on-year increase of 2
